Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that patients at high risk of developing breast cancer are recalled for MRI screening.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Women at very high risk (VHR) of breast cancer are eligible to be screened from the age of 25 years old upwards, and should be invited every year. The screening includes mammography or magnetic resonance imaging (MRI), depending on age and risk criteria.
In March, NHS England wrote to a small number of VHR women who had not been referred for annual MRI surveillance, and the National Health Service has been working hard to ensure these women are checked as a matter of urgency, as described in their individual letters. To support screening of VHR women, a new central database is planned to ensure all referrals reach NHS breast screening services.
Asked by: Peter Kyle (Labour - Hove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress his Department has made on the £100 million AI Life Sciences Accelerator Mission.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Prime Minister announced a new artificial intelligence (AI) in healthcare fund, backed by £100 million, at the AI Safety Summit. The Department for Science, Innovation and Technology is responsible for this fund, and the Department of Health and Social Care is working closely with them to identify areas where rapid deployment of AI could create transformational breakthroughs in healthcare. We are particularly focused on innovations in Life Sciences, which could accelerate our fight against devastating conditions like cancer and chronic mental ill-health, aiming to diagnose these conditions earlier and improve treatments. The Department for Science, Innovation and Technology will provide an update on our progress later in Spring.
Asked by: Dawn Butler (Labour - Brent Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the Major Conditions Strategy improves breast cancer outcomes for ethnic minority women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Reducing inequalities and improving breast cancer outcomes for ethnic minority women, including black women, is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.
NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in operational planning guidance for the health system. The Core20PLUS5 approach for adults has been rolled out as an NHS England framework to focus action on reducing inequalities on issues within the National Health Services’ direct influence, which are major contributors to inequalities in life expectancy through major conditions like cancer, cardiovascular disease, respiratory disease, and others, or Long-Term Plan priorities where stark inequalities are evident, such as maternity or severe mental illness.
The key actions for systems as highlighted in NHS England’s planning guidance for 2024/25 is to continue to deliver against the five strategic priorities for tackling health inequalities. Additionally, by the end of June 2024, NHS England aims to publish joined-up action plans to address health inequalities, and implement the Core20PLUS5 approach.
Improving earlier diagnosis of cancers, including breast cancer, is also a priority for the Government. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. Additionally, the new cancer standards developed and supported by cancer doctors and implemented in October 2023, will ensure patients are diagnosed faster, and that treatment starts earlier. In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support the delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.
Whilst the Major Conditions Strategy does not seek to describe everything that is being done, or could be done, to meet the challenges of individual conditions in silo, it instead focuses on the changes likely to make the most difference across the six groups of major conditions, including cancer.
Asked by: Dawn Butler (Labour - Brent Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve breast cancer outcomes amongst Black women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Reducing inequalities and improving breast cancer outcomes for ethnic minority women, including black women, is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.
NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in operational planning guidance for the health system. The Core20PLUS5 approach for adults has been rolled out as an NHS England framework to focus action on reducing inequalities on issues within the National Health Services’ direct influence, which are major contributors to inequalities in life expectancy through major conditions like cancer, cardiovascular disease, respiratory disease, and others, or Long-Term Plan priorities where stark inequalities are evident, such as maternity or severe mental illness.
The key actions for systems as highlighted in NHS England’s planning guidance for 2024/25 is to continue to deliver against the five strategic priorities for tackling health inequalities. Additionally, by the end of June 2024, NHS England aims to publish joined-up action plans to address health inequalities, and implement the Core20PLUS5 approach.
Improving earlier diagnosis of cancers, including breast cancer, is also a priority for the Government. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer. Additionally, the new cancer standards developed and supported by cancer doctors and implemented in October 2023, will ensure patients are diagnosed faster, and that treatment starts earlier. In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support the delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.
Whilst the Major Conditions Strategy does not seek to describe everything that is being done, or could be done, to meet the challenges of individual conditions in silo, it instead focuses on the changes likely to make the most difference across the six groups of major conditions, including cancer.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding has been provided for research into (a) lobular breast cancer and (b) other forms of breast cancer in each of the last five years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department is proud to invest £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). Department officials meet regularly to discuss a wide-range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. The NIHR invests in translational and implementation research to drive innovations into policy and practice.
We are proud to have invested £29 million into the Institute of Cancer Research (ICR) and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. This is complemented by wider investments into breast cancer research including, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, again including lobular breast cancer. Our support to the NIHR’s Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.
While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, and treatment and care, which saves lives.
Asked by: Andrew Rosindell (Conservative - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding was provided for (a) dementia and (b) cancer research in the 2022-23 financial year.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Government responsibility for delivering dementia research and dementia research funding is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science Innovation and Technology, with research delivered via UK Research and Innovation.
In 2022/23, we estimate that total Government spend on dementia research was £99.9 million, with £35.1 million of this being via the NIHR. The Department of Health and Social Care spends £1.3 billion per year on health research through the NIHR. NIHR research expenditure for all cancers was £121.8 million in 2022/23, and the NIHR spends more on cancer than any other disease group.
The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. The NIHR welcomes funding applications for research into any aspect of human health, including all cancers and dementia types. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Rebecca Long Bailey (Labour - Salford and Eccles)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to support NHS England to facilitate negotiating a better price for the drug trastuzumab deruxtecan.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is responsible for negotiating commercial agreements with individual companies, and the Department encourages companies to come forward with proposals that represent value to the taxpayer. The National Institute for Health and Care Excellence (NICE) published final draft guidance for appeal on the use of trastuzumab deruxtecan for the treatment of HER2-low metastatic or unresectable breast cancer after chemotherapy, and was unable to recommend it as a clinically and cost effective use of National Health Service resources at the price offered by the company. Following extensive discussions through late 2023 and into 2024, NHS England is no longer engaged in any active commercial negotiations on this topic, but remains available to work with the NICE, should AstraZeneca and Daiichi Sankyo be willing to offer trastuzumab deruxtecan at a price that represents value to the NHS.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.
Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.
The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.
Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.
The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.
Asked by: Ellie Reeves (Labour - Lewisham West and Penge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an estimate of the average time taken to diagnose pancreatic cancer in Lewisham West and Penge constituency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Data on the average time taken to diagnose pancreatic cancer is not published by NHS England who are responsible for publishing cancer waiting times data. NHS England is working to meet the Faster Diagnosis Standard (FDS), which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out. Latest published data from February 2024 shows FDS performance was 78.1% nationally. Of those patients referred to Lewisham and Greenwich NHS Trust in February 2024, 81.2% received a diagnosis or ruling out of cancer within four weeks which was above the 75% standard. For the same period 76.2% of patients referred to providers part of NHS South East London Integrated Care Board received a diagnosis or ruling out of cancer within 28 days.
Data on FDS does not individualise pancreatic cancer specifically, however it does include suspected upper gastrointestinal (GI) cancer, which encompasses pancreatic cancer, at provider level. Of those patients referred to Lewisham and Greenwich NHS Trust for suspected GI cancer in February 2024, 82.3% received a diagnosis or ruling out of cancer within four weeks.
The Department is taking steps to reduce cancer treatment waiting times across England, including the time between an urgent general practitioner referral and the commencement of treatment. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions her Department has had with the Department for Science, Innovation and Technology on funding for (a) the Lobular Moon Shot Project and (b) other research into lobular breast cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department invests £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). We work closely with UK Research and Innovation (UKRI) and the Medical Research Council (MRC), who are responsible for channelling a large proportion of the Department for Science, Innovation and Technology’s investments in this area. Our officials meet regularly to discuss a wide range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. While research to understand the mechanisms of cancer, including lobular breast cancer, is largely funded through UKRI and the MRC, the NIHR invests in translational and implementation research to drive innovations into policy and practice.
Launched in 2023, the Lobular Moonshot Project is a high-level funding proposal and campaign to raise money to support the Institute for Cancer Research (ICR), with whom we meet regularly, to invest in fellowships and projects in lobular breast cancer. We are proud to have invested £29 million in the ICR and Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, again including lobular breast cancer. This is complemented by wider investments into breast cancer research, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, such as lobular breast cancer. Our support to the NIHR Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.
Additionally, the NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years, the CRN has supported delivery of 10 lobular breast cancer-related studies conducted by other partners. While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, treatment, and care, which saves lives.